ROR2 levels in BAL fluid are independently associated with IPF pathogenesis and prognosis, and may serve as a useful biomarker for identifying molecular endotypes and assessing clinical risk. Exploratory findings suggest that ROR2 and its ligand may modulate prognosis in a subset of patients.
Park et al. (Fri,) studied this question.